Innovative Treatment Valencia Technologies offers a unique minimally invasive neurostimulation device, the eCoin, which provides long-term relief for urinary urge incontinence, reducing reliance on medications, frequent clinical visits, or surgical procedures. This positions the company as a leader in patient-centered, cost-effective solutions for UUI, creating opportunities to target clinics seeking advanced outpatient treatments.

Strategic Market Expansion With FDA premarket approval and recent collaborations with key urological associations, Valencia is established within the UUI treatment market and is positioned for broader adoption. Engaging with hospitals, surgery centers, and outpatient clinics that aim to improve efficiencies can unlock sales channels for their device and procedural training services.

Strong Financial Backing Valencia secured a significant investment of up to $35 million and was acquired by Boston Scientific, indicating strong financial health and validation of its technology. This support enhances credibility and opens doors for partnership opportunities, device distribution, and joint ventures within the competitive medical device landscape.